Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada

BMC Infectious Diseases

Table 5 Logistic regression model showing factors associated with clinically relevant fibrosis at end of study follow-up (N = 2419)

	APRI> 1.5 (clinically relevant fibrosis) at end of follow-up
	Univariate Analysis			Multivariable Analysis
Variable	OR	95% CI	Wald p	OR	95% CI	Wald p
Hepatitis B
Never co-infected		Reference			–
Ever co-infected	2.00	1.13–3.53	0.02
Hepatitis C
Never co-infected		Reference			Reference
Ever co-infected	7.03	4.61–10.74	< 0.0001	6.35	4.12–9.79	< 0.0001
Baseline AIDS
No ADI ever		Reference
None before/at FARVDT	1.72	0.69–4.31	0.41		–
≥ 1 before/at FARVDT	1.95	0.73–5.19
Race
White		Reference
Black	0.28	0.12–0.65
Indigenous	1.83	0.95–3.54
Asian	0.77	0.33–1.84	0.009		–
Hispanic	0.51	0.16–1.67
Other	1.00	0.35–2.84
Unknown	1.31	0.78–2.18
Birth sex
Female		Reference			–
Male	0.69	0.43–1.10	0.12
Province
BC		Reference
ON	0.44	0.28–0.70	0.0001		–
QC	0.34	0.17–0.67
Years on ARV	0.97	0.92–1.02	0.26		–
Age at first ARV	1.01	0.99–1.02	0.21		–
MSM	0.34	0.26–0.60	< 0.0001		–
PWID	5.05	3.37–7.56	< 0.0001		–
Baseline HIV viral load (Log10 copies/mL)			0.17
< 4		Reference			–
4–5	1.46	0.72–2.93
> 5	1.87	0.94–3.74
Follow-up HIV viral load (Log10 copies/mL)
< 4		Reference			Reference
4–5	3.33	1.54–7.16	< 0.0001	2.27	1.01–5.10	< 0.0001
> 5	8.80	4.41–17.43		7.33	3.46–15.51
Baseline CD4 count (cells/mm³)
≤ 100		Reference			Reference
200–349	0.55	0.35–0.86		0.62	0.38–0.99
350–499	0.15	0.06–0.42	0.0001	0.18	0.07–0.51	0.004
> 500	0.37	0.16–0.86		0.55	0.23–1.32

FARVDT first naïve ARV date, MSM Men who have Sex with Men, PWID People Who Infect Drugs
BC British Colombia, ON Ontario, QC Quebec
Variables considered in the multivariate model included: hepatitis B, hepatitis C, race, province, age at first ARV treatment, MSM, follow-up HIV viral load, baseline CD4 count. Due to co-linearity with hepatitis C, PWID was not included in the final model

ISSN: 1471-2334